Palantir Just Dropped 25% in a Month. Is It Time to Sell, or Load Up?
Yahoo! Finance ·
Key points
- Palantir reported third-quarter revenue of $2.313 billion, up 96% year over year, with U.S. commercial revenue rising 148% to $984 million, and management boosting the full-year revenue target to roughly $8.53-8.534 billion.
- Total contract value increased 6% to $2.918 billion, while U.S. commercial remaining deal value grew just 4% from June, a contrast to prior rapid growth and linked to Sovereign AI deals signing shorter terms.
- Analysts foresee revenue growth slowing from about 91% in the current year to about 53% in 2027, highlighting a potential deceleration despite strong margins.
- On November 5, Palantir fell nearly 9.7% amid broader AI and defense stock declines tied to fears of a tighter Pentagon budget under a Democratic Congress, even as government revenue rose in Q3 and commercial revenue surpassed it for the first time.
- Peers like ServiceNow and Datadog fell 41% and 39% respectively during the period, signaling a broader re-rating of AI software rather than company-specific issues, with valuations showing a wide spread between names.
- Anthropic priced its IPO at $83 and closed its first day at $97.17, placing its sales multiple near Palantir’s and complicating relative valuations in AI growth stocks.
- Palantir trades around 62x forward earnings, well below a peak multiple but still high given rising revenue, margins, and rising consensus estimates; analysts’ price targets have climbed into the $223–$248 range, suggesting a continued premium vs. near-term risk, while the upcoming February 2027 guidance remains a critical catalyst.
Summary
Palantir stock dropped about 25% in the past month despite a 96% surge in third-quarter revenue and raised full-year guidance, as investors weighed softer new-business bookings, potential Pentagon budget constraints under a Democratic Congress, and the debut of Anthropic’s IPO as a new AI benchmark. The sell-off spread across AI software peers, even as margins improved and the stock’s forward multiple narrowed from historical highs. Analysts expect growth to decelerate toward 2027, yet the company remains priced for continued expansion, with a key test coming from its first 2027 guidance in February. A measured, stepwise buy appears reasonable unless bookings resume single-digit growth or the multiple remains prohibitively high.
This summary was written with AI. The full story has every detail.